Merrill Smiles Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 201 N Center Ave, Merrill, WI 54452 Phone: 715-536-7104 Fax: 715-536-3759 |
Family Dentistry Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 301 E 2nd St, Merrill, WI 54452 Phone: 715-539-3211 |
Oakpark Dental - Merrill Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2402 E Main St, Suite 8, Merrill, WI 54452 Phone: 715-539-0441 |
Charles A. Sowieja, D.d.s., S.c. Dentist Medicare: Not Enrolled in Medicare Practice Location: 201 N Center Ave, Merrill, WI 54452 Phone: 715-535-7104 Fax: 715-536-3759 |
Quirt Family Dentistry, S.c. Dentist Medicare: Not Enrolled in Medicare Practice Location: 110 N Prospect St, Merrill, WI 54452 Phone: 715-536-3525 Fax: 715-536-7692 |
Quirt Family Dentistry - Merrill Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2812 E Main St, Merrill, WI 54452 Phone: 715-536-9628 |
News Archive
Over the next 20 years, "[c]limate change is likely to spread malaria to new areas in the Indian Himalayas, and lengthen the periods in which the infection is spread in a number of districts, according to projections [.pdf] from" researchers at the National Institute of Malaria Research (NIMR), Delhi, and published in a special issue of Current Science on Wednesday, SciDev.Net reports.
Clinical Data, Inc., today announced results from two Phase I studies of Stedivazeā¢ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).
Hispanics in smaller, more rural communities have greater barriers in accessing care than do Hispanics in larger communities, according to a report released on Thursday by the Kaiser Commission on Medicaid and the Uninsured, the Bradenton Herald reports.
Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2010 and provided an update on its corporate developments.
Out of the Middle, a coalition of leading health care providers, applauds today's introduction of the bipartisan Protecting People from Surprise Medical Bills Act.
› Verified 5 days ago